CN112210603A - Application of combined gene in esophageal squamous carcinoma - Google Patents
Application of combined gene in esophageal squamous carcinoma Download PDFInfo
- Publication number
- CN112210603A CN112210603A CN202011048576.7A CN202011048576A CN112210603A CN 112210603 A CN112210603 A CN 112210603A CN 202011048576 A CN202011048576 A CN 202011048576A CN 112210603 A CN112210603 A CN 112210603A
- Authority
- CN
- China
- Prior art keywords
- leu
- gene
- glu
- gly
- ser
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Abstract
The invention relates to the technical field of biological medicines, and discloses an application of a combined gene in preparation of a product for diagnosing esophageal squamous cell carcinoma, wherein the combined gene comprises the following genes: CCL20 gene, GSTP1 gene, HSPB1 gene, KRT14 gene, KRT15 gene, S100A8 gene, S100a9 gene, tactd 2 gene; the invention also discloses application of the combined gene in preparing a pharmaceutical composition for treating esophageal squamous carcinoma. Compared with the esophageal squamous cell carcinoma single gene expression detection in the prior art, the method has higher specificity and higher diagnosis efficiency, can obviously improve the detection sensitivity and specificity, can accurately, conveniently and efficiently carry out early diagnosis and large-scale screening of the esophageal squamous cell carcinoma, and fills the blank in the prior diagnosis technology, thereby providing effective treatment measures for patients with esophageal squamous cell carcinoma more timely and improving prognosis.
Description
Technical Field
The invention relates to the technical field of biomedicine, in particular to application of a combined gene in esophageal squamous cell carcinoma.
Background
Esophageal Cancer (EC) is a malignant tumor of the digestive tract that originates in human Esophageal epithelial cells, with the major pathological types being squamous cell carcinoma and adenocarcinoma. While the incidence of esophageal cancer rises year by year, the overall 5-year survival rate is only in the range of 15% -25%. China is a country with high incidence of esophageal cancer, the esophageal cancer becomes one of four most common malignant tumors in China, patients with advanced diseases often have serious dysphagia, malnutrition and even cachexia, the physical and mental health of the people is seriously affected, and meanwhile, the serious disease burden is brought to the society.
The adverse prognosis of esophageal cancer is closely related to the delay of diagnosis, and due to the hidden onset of esophageal cancer, atypical early symptoms and lack of an effective large-scale screening method, many patients have advanced the disease to the middle and late stages when the diagnosis is confirmed, tumors are difficult to completely resect, and lymph node involvement and distant metastasis to different degrees appear, thereby bringing great difficulty to subsequent treatment. Currently, the most common clinical methods for diagnosing esophageal cancer are upper gastrointestinal endoscopy and biopsy pathological examination, but the invasive examination has high cost and complicated operation, can bring different degrees of discomfort to the examined person, and is not suitable for large-scale application. Existing imaging examinations such as CT scans and barium contrast of the upper gastrointestinal tract also fail to meet the needs for early diagnosis and extensive screening. The traditional serum tumor marker has limited ability in early diagnosis of esophageal cancer due to its low sensitivity and specificity.
The sequencing precision of the sequencing technology reaches the level of single cells, and the further cognition of people on the cancer at the gene level is greatly promoted. Esophageal cancer is a complex disease driven by multiple genes and regulated by multiple factors, and multiple levels of products such as genomes, transcriptomes, proteomes and the like are changed in the process of disease evolution. This change is to some extent clearly tumor specific and can therefore be used for the detection of diseases. A large number of researches find that a group of biomarkers obtained by screening are jointly applied to disease diagnosis, so that the defects of poor specificity and low diagnosis efficiency of a single biomarker can be overcome, and the detection sensitivity and specificity are obviously improved. Therefore, the applicant develops a diagnosis tool capable of accurately, conveniently and efficiently performing early diagnosis and large-scale screening of the esophageal cancer by means of early screening by means of high-throughput omics technology so as to fill the blank in the existing diagnosis technology, thereby providing effective treatment measures for esophageal cancer patients more timely and improving prognosis.
Disclosure of Invention
Based on the problems, the invention provides the application of the combined gene in the esophageal squamous cell carcinoma, and the combined gene can accurately, conveniently and efficiently carry out early diagnosis and large-scale screening of the esophageal squamous cell carcinoma, fills the blank in the prior diagnosis technology, and can provide effective treatment measures for patients with the esophageal squamous cell carcinoma in time and improve prognosis.
In order to solve the technical problems, the invention provides an application of a combined gene in preparing a product for diagnosing esophageal squamous cell carcinoma, wherein the combined gene comprises the following genes: CCL20 gene, GSTP1 gene, HSPB1 gene, KRT14 gene, KRT15 gene, S100A8 gene, S100a9 gene, tactd 2 gene.
Further, the product can be combined with any one of the following detection modes to diagnose esophageal squamous carcinoma: RT-PCR, real-time quantitative PCR, immunodetection, in-situ hybridization, chip detection and high-throughput sequencing platform detection.
Further, the product comprises a reagent for detecting protein expressed by CCL20 gene, protein expressed by GSTP1 gene, protein expressed by HSPB1 gene, protein expressed by KRT14 gene, protein expressed by KRT15 gene, protein expressed by S100A8 gene, protein expressed by S100A9 gene and protein expressed by TACTD 2 gene in a sample.
Further, the product comprises a chip or a kit; wherein, the chip comprises a gene chip and a protein chip; the kit comprises a gene detection kit and a protein immunodetection kit.
In order to solve the technical problems, the invention also provides application of the combined gene in preparing a pharmaceutical composition for treating esophageal squamous cell carcinoma.
Further, the pharmaceutical composition comprises an agent that increases the expression of the combined gene, enhances the function of the expression of the combined gene, and/or enhances the activity of the expression product of the combined gene.
Further, the reagent comprises: an agent comprising a nucleic acid encoding a functional combinatorial gene secretion protein, an activator of a combinatorial gene secretion protein, an agent comprising a combinatorial gene secretion protein.
Further, the pharmaceutical composition also comprises a pharmaceutically acceptable carrier.
Compared with the prior art, the invention has the beneficial effects that: compared with the detection of the expression of a single gene of the esophageal squamous cell carcinoma in the prior art, the invention has higher specificity and higher diagnosis efficiency, can obviously improve the detection sensitivity and specificity, can accurately, conveniently and efficiently carry out early diagnosis and large-scale screening of the esophageal squamous cell carcinoma, fills the blank in the prior diagnosis technology, thereby providing effective treatment measures for patients with the esophageal squamous cell carcinoma more timely and improving the prognosis; the invention has good clinical application value, can solve the problem that the current early diagnosis and large-scale screening modes of the esophageal squamous carcinoma are limited, and is beneficial to promoting the early diagnosis and early treatment of the esophageal squamous carcinoma and improving the long-term prognosis of patients so as to relieve the burden of social diseases.
Drawings
FIG. 1 is a graph showing the control results of the concentration of CCL20 gene secreted protein in the serum of esophageal squamous carcinoma patients and healthy controls in the example of the present invention;
FIG. 2 is a graph showing the control results of the concentration of the secreted protein of GSTP1 gene in the serum of esophageal squamous carcinoma patients and healthy controls in the example of the present invention;
FIG. 3 is a graph showing the control results of the concentration of the secretory protein of the HSPB1 gene in the serum of patients with esophageal squamous carcinoma and healthy controls in the example of the present invention;
FIG. 4 is a graph showing the control results of the concentration of KRT14 gene secretory protein in the serum of patients with esophageal squamous carcinoma and healthy controls in the example of the present invention;
FIG. 5 is a graph showing the control results of the concentration of KRT15 gene secretory protein in the serum of patients with esophageal squamous carcinoma and healthy controls in the example of the present invention;
FIG. 6 is a graph showing the control results of the concentration of the secreted protein of the S100A8 gene in the serum of patients with esophageal squamous carcinoma and healthy controls in the example of the present invention;
FIG. 7 is a graph showing the control results of the concentration of the secreted protein of the S100A9 gene in the serum of patients with esophageal squamous carcinoma and healthy controls in the example of the present invention;
FIG. 8 is a graph showing the control results of the concentration of secreted protein from TACTD 2 gene in the serum of patients with esophageal squamous cell carcinoma and healthy controls in accordance with the present invention.
Detailed Description
In order to make the objects, technical solutions and advantages of the present invention more apparent, the present invention is further described in detail below with reference to examples and accompanying drawings, and the exemplary embodiments and descriptions thereof are only used for explaining the present invention and are not meant to limit the present invention.
Example (b):
this example collected primary esophageal squamous carcinoma (pathologically diagnosed) cancer and paracancerous tissue samples from thoracic surgical visits at western Washington, Sichuan university Hospital, with patient consent and approval by the institutional review Board and the ethical Committee of hospitals. And (3) rapidly transporting and digesting the sample at low temperature after the sample is separated from the body to obtain the esophageal squamous cell carcinoma single cell suspension for on-machine sequencing. In this example, cancer and paracarcinoma samples of 11 patients with esophageal squamous carcinoma were collected, and both were male patients.
This example prepared serum samples for performing ELISA indirect experiments as follows:
(1) collecting primary esophageal cancer patient (esophageal cancer pathological diagnosis) samples of Huaxi hospital of Sichuan university, wherein all samples are collected by using red-head blood sampling vessel to collect whole blood of research object
Placing the whole blood sample collected in the serum separation tube at room temperature for 2 hours, then centrifuging for 20 minutes at 1000g, taking the supernatant, storing at-80 ℃, and avoiding repeated freeze thawing;
(2) among patients with esophageal squamous carcinoma in western hospital of Sichuan university, both male and female patients were present, all control group sera were from newly developed patients with esophageal squamous carcinoma and had no history of neoadjuvant radiotherapy and chemotherapy, and normal group sera were from the physical examination group who participated in annual health physical examination and had no symptoms of any malignant tumor.
The inventor utilizes single cell sequencing to screen esophageal squamous cell carcinoma diagnosis biomarkers, and finally screens the following eight genes: CCL20 gene, GSTP1 gene, HSPB1 gene, KRT14 gene, KRT15 gene, S100A8 gene, S100a9 gene, tactd 2 gene.
The inventors verified the concentrations of the secreted proteins corresponding to the above eight genes in the sera of the patients with esophageal squamous cell carcinoma and the healthy controls by using an indirect ELISA test, and the control results are shown in fig. 1, fig. 2, fig. 3, fig. 4, fig. 5, fig. 6, fig. 7 and fig. 8, wherein the concentration in the ordinate represents the concentration, NC is the healthy control group, and ESCC is the group of patients with esophageal squamous cell carcinoma, and the results show that the expression levels of the secreted proteins such as CCL20 gene, GSTP1 gene, HSPB1 gene, KRT14 gene, KRT15 gene, S100A8 gene, S100a9 gene, and tactd 2 gene in the patients with esophageal squamous cell carcinoma are higher than those in the healthy controls.
The combined gene can be applied to the preparation of products for diagnosing esophageal squamous cell carcinoma; the product of this example can be used in combination with any of the following tests to diagnose esophageal squamous carcinoma: RT-PCR, real-time quantitative PCR, immunodetection, in-situ hybridization, chip detection and high-throughput sequencing platform detection; the product of the embodiment comprises reagents for detecting protein expressed by CCL20 gene, protein expressed by GSTP1 gene, protein expressed by HSPB1 gene, protein expressed by KRT14 gene, protein expressed by KRT15 gene, protein expressed by S100A8 gene, protein expressed by S100A9 gene and protein expressed by TACTD 2 gene in a sample; the chip of this embodiment includes gene chip and protein chip; the kit comprises a gene detection kit and a protein immunodetection kit.
The above-mentioned combined gene can also be applied to the preparation of a pharmaceutical composition for treating esophageal squamous carcinoma, the pharmaceutical composition of this embodiment includes an agent for increasing the expression of the combined gene, enhancing the expression function of the combined gene, and/or enhancing the activity of the expression product of the combined gene, and the agent of this embodiment includes: an agent comprising a nucleic acid encoding a functional combinatorial gene secreted protein, an activator of a combinatorial gene secreted protein, an agent comprising a combinatorial gene secreted protein; the pharmaceutical composition of this embodiment also includes a pharmaceutically acceptable carrier.
The above is an embodiment of the present invention. The embodiments and specific parameters in the embodiments are only for the purpose of clearly illustrating the verification process of the invention and are not intended to limit the scope of the invention, which is defined by the claims, and all equivalent structural changes made by using the contents of the specification and the drawings of the present invention should be covered by the scope of the present invention.
Sequence listing
<110> Sichuan university Hospital in western China
Application of <120> combined gene in esophageal squamous carcinoma
<130> 2020.9.8
<160> 15
<170> SIPOSequenceListing 1.0
<210> 1
<211> 96
<212> PRT
<213> Homo sapiens
<400> 1
Met Cys Cys Thr Lys Ser Leu Leu Leu Ala Ala Leu Met Ser Val Leu
1 5 10 15
Leu Leu His Leu Cys Gly Glu Ser Glu Ala Ala Ser Asn Phe Asp Cys
20 25 30
Cys Leu Gly Tyr Thr Asp Arg Ile Leu His Pro Lys Phe Ile Val Gly
35 40 45
Phe Thr Arg Gln Leu Ala Asn Glu Gly Cys Asp Ile Asn Ala Ile Ile
50 55 60
Phe His Thr Lys Lys Lys Leu Ser Val Cys Ala Asn Pro Lys Gln Thr
65 70 75 80
Trp Val Lys Tyr Ile Val Arg Leu Leu Ser Lys Lys Val Lys Asn Met
85 90 95
<210> 2
<211> 95
<212> PRT
<213> Homo sapiens
<400> 2
Met Cys Cys Thr Lys Ser Leu Leu Leu Ala Ala Leu Met Ser Val Leu
1 5 10 15
Leu Leu His Leu Cys Gly Glu Ser Glu Ala Ser Asn Phe Asp Cys Cys
20 25 30
Leu Gly Tyr Thr Asp Arg Ile Leu His Pro Lys Phe Ile Val Gly Phe
35 40 45
Thr Arg Gln Leu Ala Asn Glu Gly Cys Asp Ile Asn Ala Ile Ile Phe
50 55 60
His Thr Lys Lys Lys Leu Ser Val Cys Ala Asn Pro Lys Gln Thr Trp
65 70 75 80
Val Lys Tyr Ile Val Arg Leu Leu Ser Lys Lys Val Lys Asn Met
85 90 95
<210> 3
<211> 210
<212> PRT
<213> Homo sapiens
<400> 3
Met Pro Pro Tyr Thr Val Val Tyr Phe Pro Val Arg Gly Arg Cys Ala
1 5 10 15
Ala Leu Arg Met Leu Leu Ala Asp Gln Gly Gln Ser Trp Lys Glu Glu
20 25 30
Val Val Thr Val Glu Thr Trp Gln Glu Gly Ser Leu Lys Ala Ser Cys
35 40 45
Leu Tyr Gly Gln Leu Pro Lys Phe Gln Asp Gly Asp Leu Thr Leu Tyr
50 55 60
Gln Ser Asn Thr Ile Leu Arg His Leu Gly Arg Thr Leu Gly Leu Tyr
65 70 75 80
Gly Lys Asp Gln Gln Glu Ala Ala Leu Val Asp Met Val Asn Asp Gly
85 90 95
Val Glu Asp Leu Arg Cys Lys Tyr Ile Ser Leu Ile Tyr Thr Asn Tyr
100 105 110
Glu Ala Gly Lys Asp Asp Tyr Val Lys Ala Leu Pro Gly Gln Leu Lys
115 120 125
Pro Phe Glu Thr Leu Leu Ser Gln Asn Gln Gly Gly Lys Thr Phe Ile
130 135 140
Val Gly Asp Gln Ile Ser Phe Ala Asp Tyr Asn Leu Leu Asp Leu Leu
145 150 155 160
Leu Ile His Glu Val Leu Ala Pro Gly Cys Leu Asp Ala Phe Pro Leu
165 170 175
Leu Ser Ala Tyr Val Gly Arg Leu Ser Ala Arg Pro Lys Leu Lys Ala
180 185 190
Phe Leu Ala Ser Pro Glu Tyr Val Asn Leu Pro Ile Asn Gly Asn Gly
195 200 205
Lys Gln
210
<210> 4
<211> 205
<212> PRT
<213> Homo sapiens
<400> 4
Met Thr Glu Arg Arg Val Pro Phe Ser Leu Leu Arg Gly Pro Ser Trp
1 5 10 15
Asp Pro Phe Arg Asp Trp Tyr Pro His Ser Arg Leu Phe Asp Gln Ala
20 25 30
Phe Gly Leu Pro Arg Leu Pro Glu Glu Trp Ser Gln Trp Leu Gly Gly
35 40 45
Ser Ser Trp Pro Gly Tyr Val Arg Pro Leu Pro Pro Ala Ala Ile Glu
50 55 60
Ser Pro Ala Val Ala Ala Pro Ala Tyr Ser Arg Ala Leu Ser Arg Gln
65 70 75 80
Leu Ser Ser Gly Val Ser Glu Ile Arg His Thr Ala Asp Arg Trp Arg
85 90 95
Val Ser Leu Asp Val Asn His Phe Ala Pro Asp Glu Leu Thr Val Lys
100 105 110
Thr Lys Asp Gly Val Val Glu Ile Thr Gly Lys His Glu Glu Arg Gln
115 120 125
Asp Glu His Gly Tyr Ile Ser Arg Cys Phe Thr Arg Lys Tyr Thr Leu
130 135 140
Pro Pro Gly Val Asp Pro Thr Gln Val Ser Ser Ser Leu Ser Pro Glu
145 150 155 160
Gly Thr Leu Thr Val Glu Ala Pro Met Pro Lys Leu Ala Thr Gln Ser
165 170 175
Asn Glu Ile Thr Ile Pro Val Thr Phe Glu Ser Arg Ala Gln Leu Gly
180 185 190
Gly Pro Glu Ala Ala Lys Ser Asp Glu Thr Ala Ala Lys
195 200 205
<210> 5
<211> 472
<212> PRT
<213> Homo sapiens
<400> 5
Met Thr Thr Cys Ser Arg Gln Phe Thr Ser Ser Ser Ser Met Lys Gly
1 5 10 15
Ser Cys Gly Ile Gly Gly Gly Ile Gly Gly Gly Ser Ser Arg Ile Ser
20 25 30
Ser Val Leu Ala Gly Gly Ser Cys Arg Ala Pro Ser Thr Tyr Gly Gly
35 40 45
Gly Leu Ser Val Ser Ser Ser Arg Phe Ser Ser Gly Gly Ala Cys Gly
50 55 60
Leu Gly Gly Gly Tyr Gly Gly Gly Phe Ser Ser Ser Ser Ser Ser Phe
65 70 75 80
Gly Ser Gly Phe Gly Gly Gly Tyr Gly Gly Gly Leu Gly Ala Gly Leu
85 90 95
Gly Gly Gly Phe Gly Gly Gly Phe Ala Gly Gly Asp Gly Leu Leu Val
100 105 110
Gly Ser Glu Lys Val Thr Met Gln Asn Leu Asn Asp Arg Leu Ala Ser
115 120 125
Tyr Leu Asp Lys Val Arg Ala Leu Glu Glu Ala Asn Ala Asp Leu Glu
130 135 140
Val Lys Ile Arg Asp Trp Tyr Gln Arg Gln Arg Pro Ala Glu Ile Lys
145 150 155 160
Asp Tyr Ser Pro Tyr Phe Lys Thr Ile Glu Asp Leu Arg Asn Lys Ile
165 170 175
Leu Thr Ala Thr Val Asp Asn Ala Asn Val Leu Leu Gln Ile Asp Asn
180 185 190
Ala Arg Leu Ala Ala Asp Asp Phe Arg Thr Lys Tyr Glu Thr Glu Leu
195 200 205
Asn Leu Arg Met Ser Val Glu Ala Asp Ile Asn Gly Leu Arg Arg Val
210 215 220
Leu Asp Glu Leu Thr Leu Ala Arg Ala Asp Leu Glu Met Gln Ile Glu
225 230 235 240
Ser Leu Lys Glu Glu Leu Ala Tyr Leu Lys Lys Asn His Glu Glu Glu
245 250 255
Met Asn Ala Leu Arg Gly Gln Val Gly Gly Asp Val Asn Val Glu Met
260 265 270
Asp Ala Ala Pro Gly Val Asp Leu Ser Arg Ile Leu Asn Glu Met Arg
275 280 285
Asp Gln Tyr Glu Lys Met Ala Glu Lys Asn Arg Lys Asp Ala Glu Glu
290 295 300
Trp Phe Phe Thr Lys Thr Glu Glu Leu Asn Arg Glu Val Ala Thr Asn
305 310 315 320
Ser Glu Leu Val Gln Ser Gly Lys Ser Glu Ile Ser Glu Leu Arg Arg
325 330 335
Thr Met Gln Asn Leu Glu Ile Glu Leu Gln Ser Gln Leu Ser Met Lys
340 345 350
Ala Ser Leu Glu Asn Ser Leu Glu Glu Thr Lys Gly Arg Tyr Cys Met
355 360 365
Gln Leu Ala Gln Ile Gln Glu Met Ile Gly Ser Val Glu Glu Gln Leu
370 375 380
Ala Gln Leu Arg Cys Glu Met Glu Gln Gln Asn Gln Glu Tyr Lys Ile
385 390 395 400
Leu Leu Asp Val Lys Thr Arg Leu Glu Gln Glu Ile Ala Thr Tyr Arg
405 410 415
Arg Leu Leu Glu Gly Glu Asp Ala His Leu Ser Ser Ser Gln Phe Ser
420 425 430
Ser Gly Ser Gln Ser Ser Arg Asp Val Thr Ser Ser Ser Arg Gln Ile
435 440 445
Arg Thr Lys Val Met Asp Val His Asp Gly Lys Val Val Ser Thr His
450 455 460
Glu Gln Val Leu Arg Thr Lys Asn
465 470
<210> 6
<211> 456
<212> PRT
<213> Homo sapiens
<400> 6
Met Thr Thr Thr Phe Leu Gln Thr Ser Ser Ser Thr Phe Gly Gly Gly
1 5 10 15
Ser Thr Arg Gly Gly Ser Leu Leu Ala Gly Gly Gly Gly Phe Gly Gly
20 25 30
Gly Ser Leu Ser Gly Gly Gly Gly Ser Arg Ser Ile Ser Ala Ser Ser
35 40 45
Ala Arg Phe Val Ser Ser Gly Ser Gly Gly Gly Tyr Gly Gly Gly Met
50 55 60
Arg Val Cys Gly Phe Gly Gly Gly Ala Gly Ser Val Phe Gly Gly Gly
65 70 75 80
Phe Gly Gly Gly Val Gly Gly Gly Phe Gly Gly Gly Phe Gly Gly Gly
85 90 95
Asp Gly Gly Leu Leu Ser Gly Asn Glu Lys Ile Thr Met Gln Asn Leu
100 105 110
Asn Asp Arg Leu Ala Ser Tyr Leu Asp Lys Val Arg Ala Leu Glu Glu
115 120 125
Ala Asn Ala Asp Leu Glu Val Lys Ile His Asp Trp Tyr Gln Lys Gln
130 135 140
Thr Pro Thr Ser Pro Glu Cys Asp Tyr Ser Gln Tyr Phe Lys Thr Ile
145 150 155 160
Glu Glu Leu Arg Asp Lys Ile Met Ala Thr Thr Ile Asp Asn Ser Arg
165 170 175
Val Ile Leu Glu Ile Asp Asn Ala Arg Leu Ala Ala Asp Asp Phe Arg
180 185 190
Leu Lys Tyr Glu Asn Glu Leu Ala Leu Arg Gln Gly Val Glu Ala Asp
195 200 205
Ile Asn Gly Leu Arg Arg Val Leu Asp Glu Leu Thr Leu Ala Arg Thr
210 215 220
Asp Leu Glu Met Gln Ile Glu Gly Leu Asn Glu Glu Leu Ala Tyr Leu
225 230 235 240
Lys Lys Asn His Glu Glu Glu Met Lys Glu Phe Ser Ser Gln Leu Ala
245 250 255
Gly Gln Val Asn Val Glu Met Asp Ala Ala Pro Gly Val Asp Leu Thr
260 265 270
Arg Val Leu Ala Glu Met Arg Glu Gln Tyr Glu Ala Met Ala Glu Lys
275 280 285
Asn Arg Arg Asp Val Glu Ala Trp Phe Phe Ser Lys Thr Glu Glu Leu
290 295 300
Asn Lys Glu Val Ala Ser Asn Thr Glu Met Ile Gln Thr Ser Lys Thr
305 310 315 320
Glu Ile Thr Asp Leu Arg Arg Thr Met Gln Glu Leu Glu Ile Glu Leu
325 330 335
Gln Ser Gln Leu Ser Met Lys Ala Gly Leu Glu Asn Ser Leu Ala Glu
340 345 350
Thr Glu Cys Arg Tyr Ala Thr Gln Leu Gln Gln Ile Gln Gly Leu Ile
355 360 365
Gly Gly Leu Glu Ala Gln Leu Ser Glu Leu Arg Cys Glu Met Glu Ala
370 375 380
Gln Asn Gln Glu Tyr Lys Met Leu Leu Asp Ile Lys Thr Arg Leu Glu
385 390 395 400
Gln Glu Ile Ala Thr Tyr Arg Ser Leu Leu Glu Gly Gln Asp Ala Lys
405 410 415
Met Ala Gly Ile Ala Ile Arg Glu Ala Ser Ser Gly Gly Gly Gly Ser
420 425 430
Ser Ser Asn Phe His Ile Asn Val Glu Glu Ser Val Asp Gly Gln Val
435 440 445
Val Ser Ser His Lys Arg Glu Ile
450 455
<210> 7
<211> 463
<212> PRT
<213> Homo sapiens
<400> 7
Met Thr Thr Thr Phe Leu Gln Thr Ser Ser Ser Thr Phe Gly Gly Gly
1 5 10 15
Ser Thr Arg Gly Gly Ser Leu Leu Ala Gly Gly Gly Gly Phe Gly Gly
20 25 30
Gly Ser Leu Ser Gly Gly Gly Gly Ser Arg Ser Ile Ser Ala Ser Ser
35 40 45
Ala Arg Phe Val Ser Ser Gly Ser Gly Gly Gly Tyr Gly Gly Gly Met
50 55 60
Arg Val Cys Gly Phe Gly Gly Gly Ala Gly Ser Val Phe Gly Gly Gly
65 70 75 80
Phe Gly Gly Gly Val Gly Gly Gly Phe Gly Gly Gly Phe Gly Gly Gly
85 90 95
Asp Gly Gly Leu Leu Ser Gly Asn Glu Lys Ile Thr Met Gln Asn Leu
100 105 110
Asn Asp Arg Leu Ala Ser Tyr Leu Asp Lys Val Arg Ala Leu Glu Glu
115 120 125
Ala Asn Ala Asp Leu Glu Val Lys Ile His Asp Trp Tyr Gln Lys Gln
130 135 140
Thr Pro Thr Ser Pro Glu Cys Asp Tyr Ser Gln Tyr Phe Lys Thr Ile
145 150 155 160
Glu Glu Leu Arg Asp Lys Ile Met Ala Thr Thr Ile Asp Asn Ser Arg
165 170 175
Val Ile Leu Glu Ile Asp Asn Ala Arg Leu Ala Ala Asp Asp Phe Arg
180 185 190
Leu Lys Tyr Glu Asn Glu Leu Ala Leu Arg Gln Gly Val Glu Ala Asp
195 200 205
Ile Asn Gly Leu Arg Arg Val Leu Asp Glu Leu Thr Leu Ala Arg Thr
210 215 220
Asp Leu Glu Met Gln Ile Glu Gly Leu Asn Glu Glu Leu Ala Tyr Leu
225 230 235 240
Lys Lys Asn His Glu Glu Trp Val Pro Pro Ile Leu Gln Glu Met Lys
245 250 255
Glu Phe Ser Ser Gln Leu Ala Gly Gln Val Asn Val Glu Met Asp Ala
260 265 270
Ala Pro Gly Val Asp Leu Thr Arg Val Leu Ala Glu Met Arg Glu Gln
275 280 285
Tyr Glu Ala Met Ala Glu Lys Asn Arg Arg Asp Val Glu Ala Trp Phe
290 295 300
Phe Ser Lys Thr Glu Glu Leu Asn Lys Glu Val Ala Ser Asn Thr Glu
305 310 315 320
Met Ile Gln Thr Ser Lys Thr Glu Ile Thr Asp Leu Arg Arg Thr Met
325 330 335
Gln Glu Leu Glu Ile Glu Leu Gln Ser Gln Leu Ser Met Lys Ala Gly
340 345 350
Leu Glu Asn Ser Leu Ala Glu Thr Glu Cys Arg Tyr Ala Thr Gln Leu
355 360 365
Gln Gln Ile Gln Gly Leu Ile Gly Gly Leu Glu Ala Gln Leu Ser Glu
370 375 380
Leu Arg Cys Glu Met Glu Ala Gln Asn Gln Glu Tyr Lys Met Leu Leu
385 390 395 400
Asp Ile Lys Thr Arg Leu Glu Gln Glu Ile Ala Thr Tyr Arg Ser Leu
405 410 415
Leu Glu Gly Gln Asp Ala Lys Met Ala Gly Ile Ala Ile Arg Glu Ala
420 425 430
Ser Ser Gly Gly Gly Gly Ser Ser Ser Asn Phe His Ile Asn Val Glu
435 440 445
Glu Ser Val Asp Gly Gln Val Val Ser Ser His Lys Arg Glu Ile
450 455 460
<210> 8
<211> 437
<212> PRT
<213> Homo sapiens
<400> 8
Met Thr Thr Thr Phe Leu Gln Thr Ser Ser Ser Thr Phe Gly Gly Gly
1 5 10 15
Ser Thr Arg Gly Gly Ser Leu Leu Ala Gly Gly Gly Gly Phe Gly Gly
20 25 30
Gly Ser Leu Ser Gly Gly Gly Gly Ser Arg Ser Ile Ser Ala Ser Ser
35 40 45
Ala Arg Phe Val Ser Ser Gly Ser Gly Gly Gly Tyr Gly Gly Gly Met
50 55 60
Arg Val Cys Gly Phe Gly Gly Gly Ala Gly Ser Val Phe Gly Gly Gly
65 70 75 80
Phe Gly Gly Gly Val Gly Gly Gly Phe Gly Gly Gly Phe Gly Gly Gly
85 90 95
Asp Gly Gly Leu Leu Ser Gly Asn Glu Lys Ile Thr Met Gln Asn Leu
100 105 110
Asn Asp Arg Leu Ala Ser Tyr Leu Asp Lys Val Arg Ala Leu Glu Glu
115 120 125
Ala Asn Ala Asp Leu Glu Val Lys Ile His Asp Trp Tyr Gln Lys Gln
130 135 140
Thr Pro Thr Ser Pro Glu Cys Asp Tyr Ser Gln Tyr Phe Lys Thr Ile
145 150 155 160
Glu Glu Leu Arg Asp Lys Ile Met Ala Thr Thr Ile Asp Asn Ser Arg
165 170 175
Val Ile Leu Glu Ile Asp Asn Ala Arg Leu Ala Ala Asp Asp Phe Arg
180 185 190
Leu Lys Tyr Glu Asn Glu Leu Ala Leu Arg Gln Gly Val Glu Ala Asp
195 200 205
Ile Asn Gly Leu Arg Arg Val Leu Asp Glu Leu Thr Leu Ala Arg Thr
210 215 220
Asp Leu Glu Met Gln Ile Glu Gly Leu Asn Glu Glu Leu Ala Tyr Leu
225 230 235 240
Lys Lys Asn His Glu Glu Trp Val Pro Pro Ile Leu Gln Glu Met Lys
245 250 255
Glu Phe Ser Ser Gln Leu Ala Gly Gln Val Asn Val Glu Met Asp Ala
260 265 270
Ala Pro Gly Val Asp Leu Thr Arg Val Leu Ala Glu Met Arg Glu Gln
275 280 285
Tyr Glu Ala Met Ala Glu Lys Asn Arg Arg Asp Val Glu Ala Trp Phe
290 295 300
Phe Ser Lys Thr Glu Glu Leu Asn Lys Glu Val Ala Ser Asn Thr Glu
305 310 315 320
Met Ile Gln Thr Ser Lys Thr Glu Ile Thr Asp Leu Arg Arg Thr Met
325 330 335
Gln Glu Leu Glu Ile Glu Leu Gln Ser Gln Leu Ser Met Lys Ala Gly
340 345 350
Leu Glu Asn Ser Leu Ala Glu Thr Glu Cys Arg Tyr Ala Thr Gln Leu
355 360 365
Gln Gln Ile Gln Gly Leu Ile Gly Gly Leu Glu Ala Gln Leu Ser Glu
370 375 380
Leu Arg Cys Glu Met Glu Ala Gln Asn Gln Glu Tyr Lys Met Leu Leu
385 390 395 400
Asp Ile Lys Thr Arg Leu Glu Gln Glu Ile Ala Thr Tyr Arg Ser Leu
405 410 415
Leu Glu Gly Gln Asp Ala Lys Met Ala Gly Ile Ala Ile Arg Glu Ala
420 425 430
Tyr Ser Phe Ser Leu
435
<210> 9
<211> 93
<212> PRT
<213> Homo sapiens
<400> 9
Met Leu Thr Glu Leu Glu Lys Ala Leu Asn Ser Ile Ile Asp Val Tyr
1 5 10 15
His Lys Tyr Ser Leu Ile Lys Gly Asn Phe His Ala Val Tyr Arg Asp
20 25 30
Asp Leu Lys Lys Leu Leu Glu Thr Glu Cys Pro Gln Tyr Ile Arg Lys
35 40 45
Lys Gly Ala Asp Val Trp Phe Lys Glu Leu Asp Ile Asn Thr Asp Gly
50 55 60
Ala Val Asn Phe Gln Glu Phe Leu Ile Leu Val Ile Lys Met Gly Val
65 70 75 80
Ala Ala His Lys Lys Ser His Glu Glu Ser His Lys Glu
85 90
<210> 10
<211> 117
<212> PRT
<213> Homo sapiens
<400> 10
Met Ser Leu Val Ser Cys Leu Ser Glu Asp Leu Lys Val Leu Phe Phe
1 5 10 15
Arg Trp Gly Lys Ser Val Gly Ile Met Leu Thr Glu Leu Glu Lys Ala
20 25 30
Leu Asn Ser Ile Ile Asp Val Tyr His Lys Tyr Ser Leu Ile Lys Gly
35 40 45
Asn Phe His Ala Val Tyr Arg Asp Asp Leu Lys Lys Leu Leu Glu Thr
50 55 60
Glu Cys Pro Gln Tyr Ile Arg Lys Lys Gly Ala Asp Val Trp Phe Lys
65 70 75 80
Glu Leu Asp Ile Asn Thr Asp Gly Ala Val Asn Phe Gln Glu Phe Leu
85 90 95
Ile Leu Val Ile Lys Met Gly Val Ala Ala His Lys Lys Ser His Glu
100 105 110
Glu Ser His Lys Glu
115
<210> 11
<211> 116
<212> PRT
<213> Homo sapiens
<400> 11
Met Ser Leu Val Ser Cys Leu Ser Glu Asp Leu Val Leu Phe Phe Arg
1 5 10 15
Trp Gly Lys Ser Val Gly Ile Met Leu Thr Glu Leu Glu Lys Ala Leu
20 25 30
Asn Ser Ile Ile Asp Val Tyr His Lys Tyr Ser Leu Ile Lys Gly Asn
35 40 45
Phe His Ala Val Tyr Arg Asp Asp Leu Lys Lys Leu Leu Glu Thr Glu
50 55 60
Cys Pro Gln Tyr Ile Arg Lys Lys Gly Ala Asp Val Trp Phe Lys Glu
65 70 75 80
Leu Asp Ile Asn Thr Asp Gly Ala Val Asn Phe Gln Glu Phe Leu Ile
85 90 95
Leu Val Ile Lys Met Gly Val Ala Ala His Lys Lys Ser His Glu Glu
100 105 110
Ser His Lys Glu
115
<210> 12
<211> 101
<212> PRT
<213> Homo sapiens
<400> 12
Met Trp Gly Lys Ser Val Gly Ile Met Leu Thr Glu Leu Glu Lys Ala
1 5 10 15
Leu Asn Ser Ile Ile Asp Val Tyr His Lys Tyr Ser Leu Ile Lys Gly
20 25 30
Asn Phe His Ala Val Tyr Arg Asp Asp Leu Lys Lys Leu Leu Glu Thr
35 40 45
Glu Cys Pro Gln Tyr Ile Arg Lys Lys Gly Ala Asp Val Trp Phe Lys
50 55 60
Glu Leu Asp Ile Asn Thr Asp Gly Ala Val Asn Phe Gln Glu Phe Leu
65 70 75 80
Ile Leu Val Ile Lys Met Gly Val Ala Ala His Lys Lys Ser His Glu
85 90 95
Glu Ser His Lys Glu
100
<210> 13
<211> 93
<212> PRT
<213> Homo sapiens
<400> 13
Met Leu Thr Glu Leu Glu Lys Ala Leu Asn Ser Ile Ile Asp Val Tyr
1 5 10 15
His Lys Tyr Ser Leu Ile Lys Gly Asn Phe His Ala Val Tyr Arg Asp
20 25 30
Asp Leu Lys Lys Leu Leu Glu Thr Glu Cys Pro Gln Tyr Ile Arg Lys
35 40 45
Lys Gly Ala Asp Val Trp Phe Lys Glu Leu Asp Ile Asn Thr Asp Gly
50 55 60
Ala Val Asn Phe Gln Glu Phe Leu Ile Leu Val Ile Lys Met Gly Val
65 70 75 80
Ala Ala His Lys Lys Ser His Glu Glu Ser His Lys Glu
85 90
<210> 14
<211> 114
<212> PRT
<213> Homo sapiens
<400> 14
Met Thr Cys Lys Met Ser Gln Leu Glu Arg Asn Ile Glu Thr Ile Ile
1 5 10 15
Asn Thr Phe His Gln Tyr Ser Val Lys Leu Gly His Pro Asp Thr Leu
20 25 30
Asn Gln Gly Glu Phe Lys Glu Leu Val Arg Lys Asp Leu Gln Asn Phe
35 40 45
Leu Lys Lys Glu Asn Lys Asn Glu Lys Val Ile Glu His Ile Met Glu
50 55 60
Asp Leu Asp Thr Asn Ala Asp Lys Gln Leu Ser Phe Glu Glu Phe Ile
65 70 75 80
Met Leu Met Ala Arg Leu Thr Trp Ala Ser His Glu Lys Met His Glu
85 90 95
Gly Asp Glu Gly Pro Gly His His His Lys Pro Gly Leu Gly Glu Gly
100 105 110
Thr Pro
<210> 15
<211> 323
<212> PRT
<213> Homo sapiens
<400> 15
Met Ala Arg Gly Pro Gly Leu Ala Pro Pro Pro Leu Arg Leu Pro Leu
1 5 10 15
Leu Leu Leu Val Leu Ala Ala Val Thr Gly His Thr Ala Ala Gln Asp
20 25 30
Asn Cys Thr Cys Pro Thr Asn Lys Met Thr Val Cys Ser Pro Asp Gly
35 40 45
Pro Gly Gly Arg Cys Gln Cys Arg Ala Leu Gly Ser Gly Met Ala Val
50 55 60
Asp Cys Ser Thr Leu Thr Ser Lys Cys Leu Leu Leu Lys Ala Arg Met
65 70 75 80
Ser Ala Pro Lys Asn Ala Arg Thr Leu Val Arg Pro Ser Glu His Ala
85 90 95
Leu Val Asp Asn Asp Gly Leu Tyr Asp Pro Asp Cys Asp Pro Glu Gly
100 105 110
Arg Phe Lys Ala Arg Gln Cys Asn Gln Thr Ser Val Cys Trp Cys Val
115 120 125
Asn Ser Val Gly Val Arg Arg Thr Asp Lys Gly Asp Leu Ser Leu Arg
130 135 140
Cys Asp Glu Leu Val Arg Thr His His Ile Leu Ile Asp Leu Arg His
145 150 155 160
Arg Pro Thr Ala Gly Ala Phe Asn His Ser Asp Leu Asp Ala Glu Leu
165 170 175
Arg Arg Leu Phe Arg Glu Arg Tyr Arg Leu His Pro Lys Phe Val Ala
180 185 190
Ala Val His Tyr Glu Gln Pro Thr Ile Gln Ile Glu Leu Arg Gln Asn
195 200 205
Thr Ser Gln Lys Ala Ala Gly Asp Val Asp Ile Gly Asp Ala Ala Tyr
210 215 220
Tyr Phe Glu Arg Asp Ile Lys Gly Glu Ser Leu Phe Gln Gly Arg Gly
225 230 235 240
Gly Leu Asp Leu Arg Val Arg Gly Glu Pro Leu Gln Val Glu Arg Thr
245 250 255
Leu Ile Tyr Tyr Leu Asp Glu Ile Pro Pro Lys Phe Ser Met Lys Arg
260 265 270
Leu Thr Ala Gly Leu Ile Ala Val Ile Val Val Val Val Val Ala Leu
275 280 285
Val Ala Gly Met Ala Val Leu Val Ile Thr Asn Arg Arg Lys Ser Gly
290 295 300
Lys Tyr Lys Lys Val Glu Ile Lys Glu Leu Gly Glu Leu Arg Lys Glu
305 310 315 320
Pro Ser Leu
Claims (8)
1. The application of the combined gene in preparing products for diagnosing esophageal squamous cell carcinoma is characterized in that the combined gene comprises the following genes: CCL20 gene, GSTP1 gene, HSPB1 gene, KRT14 gene, KRT15 gene, S100A8 gene, S100a9 gene, tactd 2 gene.
2. The use according to claim 1, wherein the product is used for the diagnosis of esophageal squamous carcinoma in combination with any of the following tests: RT-PCR, real-time quantitative PCR, immunodetection, in-situ hybridization, chip detection and high-throughput sequencing platform detection.
3. The use of claim 1, wherein the product comprises a reagent for detecting a protein expressed by the CCL20 gene, a protein expressed by the GSTP1 gene, a protein expressed by the HSPB1 gene, a protein expressed by the KRT14 gene, a protein expressed by the KRT15 gene, a protein expressed by the S100A8 gene, a protein expressed by the S100a9 gene, and a protein expressed by the tactd 2 gene in a sample.
4. The use of claim 1, wherein the product comprises a chip or kit; wherein, the chip comprises a gene chip and a protein chip; the kit comprises a gene detection kit and a protein immunodetection kit.
5. Use of the combined gene of claim 1 for preparing a pharmaceutical composition for treating esophageal squamous carcinoma.
6. The use of claim 5, wherein the pharmaceutical composition comprises an agent that increases expression, enhances function of expression, and/or enhances activity of an expression product of the combined gene.
7. The use according to claim 6, wherein the agent comprises: an agent comprising a nucleic acid encoding a functional combinatorial gene secretion protein, an activator of a combinatorial gene secretion protein, an agent comprising a combinatorial gene secretion protein.
8. The use of claim 5, wherein the pharmaceutical composition further comprises a pharmaceutically acceptable carrier.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011048576.7A CN112210603A (en) | 2020-09-29 | 2020-09-29 | Application of combined gene in esophageal squamous carcinoma |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011048576.7A CN112210603A (en) | 2020-09-29 | 2020-09-29 | Application of combined gene in esophageal squamous carcinoma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112210603A true CN112210603A (en) | 2021-01-12 |
Family
ID=74051998
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011048576.7A Pending CN112210603A (en) | 2020-09-29 | 2020-09-29 | Application of combined gene in esophageal squamous carcinoma |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112210603A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114381527A (en) * | 2022-01-29 | 2022-04-22 | 中山大学孙逸仙纪念医院 | Novel biomarker for esophageal cancer immunotherapy prognosis and application |
-
2020
- 2020-09-29 CN CN202011048576.7A patent/CN112210603A/en active Pending
Non-Patent Citations (7)
| Title |
|---|
| HUA SU等: ""Global gene expression profiling and validation in esophageal squamous cell carcinoma (ESCC) and its association with clinical phenotypes"", <NIH PUBLIC ACCESS> * |
| JIAN-BO LIN等: ""KRT 15 as a prognostic biomarker is highly expressed in esophageal carcinoma"", <FUTURE MEDICINE> * |
| JUNFANG JI等: ""Differential expression of S100 gene family in human esophageal squamous cell carcinoma"", <J CANCER RES CLIN ONCOL> * |
| YAN ZHANG等: ""Expression of Heat Shock Protein-27 (Hsp27) and P38MAPK in Esophageal Squamous Cell Carcinoma"", <CLINICAL RESEARCH> * |
| YUSUKE YAMAMOTO: ""Significance of GSTP1 for predicting the prognosis and chemotherapeutic efficacy in esophageal squamous cell carcinoma"", <ONCOLOGY REPORTS> * |
| ZHIXIANG LI等: ""Clinical Significance of Serum Chemokines in Esophageal Cancer"", <CLINICAL RESEARCH> * |
| 武丹等: ""TACSTD2 调控食管鳞癌细胞对顺铂的敏感性"", <江苏大学学报( 医学版)> * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114381527A (en) * | 2022-01-29 | 2022-04-22 | 中山大学孙逸仙纪念医院 | Novel biomarker for esophageal cancer immunotherapy prognosis and application |
| CN114381527B (en) * | 2022-01-29 | 2022-08-02 | 中山大学孙逸仙纪念医院 | Novel biomarker for esophageal cancer immunotherapy prognosis and application |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111172279A (en) | Model for diagnosing lung cancer by combined detection of peripheral blood methylation gene and IDH1 | |
| CN109557311B (en) | Colorectal cancer diagnosis marker, colorectal cancer detection product and application thereof | |
| CN108949997A (en) | A kind of lung cancer detection marker and diagnostic kit | |
| CN110484624A (en) | A kind of gastric cancer biomarker and its detection method and application based on peripheral blood | |
| CN104711341A (en) | Application of DLK1 gene in preparation of gastrointestinal stromal tumor diagnostic reagent | |
| CN112210603A (en) | Application of combined gene in esophageal squamous carcinoma | |
| CN107460241B (en) | Application of exosome small-molecule RNA in acute myocardial infarction risk assessment | |
| Wu et al. | Serum alkaline phosphatase predicts poor disease-free survival in patients receiving radical gastrectomy | |
| CN108152508A (en) | A kind of screening technique of hurtless measure gastric cancer saliva biomarker | |
| KR102211972B1 (en) | Method for early diagnosis of breast cancer and monitoring after treatment using liquid biopsy multi-cancer gene biomarkers | |
| WO2023050642A1 (en) | Application of alpha-fetoprotein or carcinoembryonic antigen combined with gene marker in tumor diagnosis | |
| RU2360924C1 (en) | Marker of prostate gland cancer | |
| RU2612021C1 (en) | Method of predicting risk of gastric adenocarcinoma development in case of chronic processes of ulcer formation in organ | |
| JP7398226B2 (en) | Methods for assessing the risk of developing colorectal cancer | |
| CN113817824A (en) | Tumor gene diagnosis marker combined with carcinoembryonic antigen and application thereof | |
| CN109722480B (en) | Non-small cell lung cancer detection kit and application thereof | |
| CN111690746A (en) | Platelet RNA marker related to lung cancer and application thereof | |
| Röbeck et al. | Multiplex protein analysis and ensemble machine learning methods of fine needle aspirates from prostate cancer patients reveal potential diagnostic signatures associated with tumour grade | |
| CN106282360B (en) | A kind of blood plasma miRNA combination, its probe compositions and application for colon cancer prediction transfer | |
| Schrump | Circulating tumor DNA: Solid data from liquid biopsies | |
| CN109182514A (en) | Pulmonary cancer diagnosis or transfer diagnosis marker LncRNA Loc729658 and kit and its application | |
| CN108431029A (en) | The marker of papillary-mucinous tumor in cancer of pancreas and ductus pancreaticus | |
| CN116298292B (en) | Application of GNG2 protein detection reagent in preparation of products for diagnosing and prognosing colon cancer | |
| RU2802446C2 (en) | Method of prediction of outcomes in patients with squamous cell cancer of the oral mucosa | |
| CN111662985B (en) | Application of microRNA combined CEA in preparation of cervical cancer early diagnosis kit |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210112 |
|
| RJ01 | Rejection of invention patent application after publication |